<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30361894</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1752-153X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>25</Day>                    </PubDate>                </JournalIssue>                <Title>Chemistry Central journal</Title>                <ISOAbbreviation>Chem Cent J</ISOAbbreviation>            </Journal>            <ArticleTitle>Estrogen alpha receptor antagonists for the treatment of breast cancer: a review.</ArticleTitle>            <Pagination>                <MedlinePgn>107</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13065-018-0472-8</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer is at present one of the leading causes of death in the world. It accounts for 13% of deaths occurred worldwide and is continuously rising, with an estimated million of deaths up to 2030. Due to poor availability of prevention, diagnosis and treatment of breast cancer, the rate of mortality is at alarming level globally. In women, hormone-dependent estrogen receptor positive (ER+) breast cancer making up approximately 75% of all breast cancers. Hence, it has drawn the extensive attention of researchers towards the development of effective drugs for the treatment of hormone-dependent breast cancer. Estrogen, a female sex hormone has a vital role in the initiation and progression of breast malignancy. Therefore, estrogen receptor is the central target for the treatment of breast cancer.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this review, we have studied various classes of antiestrogens that have been designed and synthesized with selective binding for estrogen alpha receptor (ER). Since estrogen receptor Î± is mainly responsible for the breast cancer initiation and progression, therefore there is need of promising strategies for the design and synthesis of new therapeutic ligands which selectively bind to estrogen alpha receptor and inhibit estrogen dependent proliferative activity.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sharma</LastName>                    <ForeName>Deepika</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kumar</LastName>                    <ForeName>Sanjiv</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Narasimhan</LastName>                    <ForeName>Balasubramanian</ForeName>                    <Initials>B</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9627-094X</Identifier>                    <AffiliationInfo>                        <Affiliation>Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India. naru2000us@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Chem Cent J</MedlineTA>            <NlmUniqueID>101314213</NlmUniqueID>            <ISSNLinking>1752-153X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Antiestrogens</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Estrogen receptor alpha</Keyword>            <Keyword MajorTopicYN="N">Molecular docking</Keyword>            <Keyword MajorTopicYN="N">Relative binding affinity</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30361894</ArticleId>            <ArticleId IdType="doi">10.1186/s13065-018-0472-8</ArticleId>            <ArticleId IdType="pii">10.1186/s13065-018-0472-8</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>